CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 119 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,181,169 | -77.3% | 146,289 | -83.3% | 0.01% | -75.0% |
| Q2 2023 | $9,590,974 | -22.5% | 875,888 | -38.3% | 0.02% | -31.4% |
| Q1 2023 | $12,378,389 | +407.4% | 1,419,540 | +264.8% | 0.04% | +337.5% |
| Q4 2022 | $2,439,638 | +132.6% | 389,097 | +29.8% | 0.01% | +100.0% |
| Q3 2022 | $1,049,000 | +215.0% | 299,747 | +165.5% | 0.00% | +300.0% |
| Q2 2022 | $333,000 | +25.2% | 112,910 | +32.2% | 0.00% | 0.0% |
| Q1 2022 | $266,000 | +180.0% | 85,414 | +204.0% | 0.00% | – |
| Q4 2021 | $95,000 | -92.0% | 28,100 | -89.6% | 0.00% | -100.0% |
| Q2 2021 | $1,183,000 | -74.6% | 271,216 | -73.6% | 0.00% | -75.0% |
| Q1 2021 | $4,664,000 | -27.2% | 1,027,236 | -7.9% | 0.01% | -33.3% |
| Q4 2020 | $6,403,000 | +261.1% | 1,115,477 | +355.5% | 0.02% | +200.0% |
| Q3 2020 | $1,773,000 | +64.8% | 244,893 | -20.6% | 0.01% | +20.0% |
| Q2 2020 | $1,076,000 | +125.6% | 308,269 | -4.3% | 0.01% | +25.0% |
| Q1 2020 | $477,000 | -37.3% | 322,063 | -17.1% | 0.00% | +100.0% |
| Q4 2019 | $761,000 | +417.7% | 388,308 | +1253.0% | 0.00% | – |
| Q3 2019 | $147,000 | – | 28,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |